Navigation Links
Genomma Lab Announces 2009 Earnings Guidance
Date:12/10/2008

MEXICO CITY, Dec. 10 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), a leading Mexican over-the-counter ("OTC") pharmaceuticals and personal care products company, announced today its 2009 earnings guidance. The Company expects to reach organic growth without considering acquisitions in the range of 21% - 22% in net sales and an EBITDA(I) margin in the range of 27% - 28%. These estimates are based on the organic growth of core products (products launched during and before 2007); the full year effect in sales of those products launched during 2008; the growth of Genomma Lab's international operations; as well as the Company's launch program of product line extensions and new brands in new categories and in those in which the Company already participates.

Genomma Lab expects to maintain its strategy of brand acquisitions and, on a timely basis, will inform the market on any completed transaction, as well as the corresponding change to the Company's earnings guidance. As of the close of the third quarter 2008, the Company had a cash balance and equivalents of Ps. 1,073 million that may be used partially or totally for potential brand acquisitions.

Genomma Lab will continue its efforts to increase its share in the Mexican personal care and over-the-counter markets. The value of such markets is approximately Ps. 75 billion(II) and Ps. 19 billion(III), respectively.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico with international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share.

Genomma Lab performed its Initial Public Offering in June 2008, through a combined offering (mainly primary) and is listed on the Mexican Stock Exchange under the ticker symbol "LAB" (Bloomberg: labb.mx).

    Web Site: www.genommalab.com

      (I) EBITDA is defined as Operating Income plus Depreciation and
          Amortization
     (II) Source:  Euromonitor (2006)
    (III) Source:  Datamonitor (2007)

    Investor Relations in Mexico City:
    Tel: +52 (55) 5081 0000 Ext. 4250
    E-mail: inversion@genommalab.com

    In New York:
    i-advize Corporate Communications, Inc.
    Tel: (212) 406-3692
    E-mail: genomma@i-advize.com

'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genomma Lab Internacional Acquires UNIGASTROZOL
2. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
3. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
4. WellPoint Announces Appointment of Andrew J. Lang as Senior Vice President of Application Development
5. Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals
6. Markel Corporation Announces New DataBreach(SM) Privacy Liability Coverage
7. Allscripts Announces Expiration of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024
8. Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt
9. Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
10. American Lung Association Announces Support of Pickens Plan
11. MassMutual Announces LEED-EB Certification Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... On Dec. ... the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who have ... (MPNs) by going above and beyond the standard of care, demonstrating leadership within the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... the launch of its 60-day free trial program for all of the company’s ... the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of ... of an injury, patients must find the one that works for them. When an ... created a machine that worked and decided to share it with others. , He ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  The Addiction Treatment ... Academy of Managed Care Pharmacy (AMCP), has released ... better address the opioid addiction crisis, including through ... (MAT). ATAG,s newly released paper, "The ... to Naloxone," addresses many issues around gaps and ...
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
(Date:12/2/2016)... Dec. 2, 2016   CytoSorbents Corporation (NASDAQ: ... its European Union approved CytoSorb ® cytokine adsorber ... patients worldwide, announced that Dr. Phillip Chan , ... Annual LD Micro Main Event investor conference held ... the Luxe Sunset Boulevard Hotel in Los ...
Breaking Medicine Technology: